Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NovaBay Pharmaceuticals Inc (NYSE MKT LLC:NBY)

Delayed Data
As of Feb 09
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

NovaBay Pharmaceuticals, Inc. engages in developing compounds to address the unmet therapeutic needs. It operates through the following segments: Dermatology, Ophthalmology, Urology, Wound Care, and Others. The Dermatology segment includes all aspects of its business around the dermatology arena including the collaboration with Galderma and their impetigo clinical trial. The Ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The Urology segment covers its urinary catheter encrustation and blockage (UCBE) trials. The Wound Care segment encompasses the business around its NeutroPhase product. The Others segment are immaterial and are shown as an aggregate. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Contact Information

NovaBay Pharmaceuticals, Inc.
5980 Horton Street
Emeryville California 94608
P:(510) 899-8800
Investor Relations:
(510) 899-8809



Other institutional1.65%
Mutual fund holders1.30%
Individual stakeholders1.25%

Top Executives

Mark M. SieczkarekChairman, President & Chief Executive Officer
Thomas J. PaulsonCFO, CAO, Secretary & Treasurer
Roy J. WuSenior VP-Business & Corporate Development
David W. StromanSenior Vice President-Ophthalmology
Glenn MoroVice President-Sales & Marketing